European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
revised:
10
11
2021
received:
18
07
2021
accepted:
18
11
2021
pubmed:
16
12
2021
medline:
19
2
2022
entrez:
15
12
2021
Statut:
ppublish
Résumé
The introduction of immune checkpoint inhibitors (ICIs) opened a new era in oncologic therapy. The favourable profile of ICIs in terms of efficacy and safety can be overshadowed by the development of immune-related adverse events (irAEs). Dermatologic irAEs (dirAEs) appear in about 40% of patients undergoing immunotherapy and mainly include maculopapular, psoriasiform, lichenoid and eczematous rashes, auto-immune bullous disorders, pigmentary disorders, pruritus, oral mucosal lesions, hair and nail changes, as well as a few rare and potentially life-threatening toxicities. The EADV task force Dermatology for Cancer Patients merged the clinical experience of the so-far published data, incorporated the quantitative and qualitative characteristics of each specific dirAEs, and released dermatology-derived, phenotype-specific treatment recommendations for cutaneous toxicities (including levels of evidence and grades of recommendation). The basic principle of management is that the interventions should be tailored to serve the equilibrium between patients' relief from the symptoms and signs of skin toxicity and the preservation of an unimpeded oncologic treatment.
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
332-350Informations de copyright
© 2021 European Academy of Dermatology and Venereology.
Références
Esfahani K, Elkrief A, Calabrese C et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol 2020; 17: 504-515.
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378: 158-168.
Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: Update on management of immune-related toxicities. Transl Lung Cancer Res 2015; 4: 560-575.
Apalla Z, Papageorgiou C, Lallas A et al. Cutaneous adverse events of immune checkpoint inhibitors: a literature review. Dermatol Pract Concept 2021; 11: e2021155.
Sanlorenzo M, Vujic I, Daud A et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 2015; 151: 1206-1212.
Chan L, Hwang SJE, Byth K et al. Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events. J Am Acad Dermatol 2020; 82: 311-316.
Matsuya T, Nakamura Y, Matsushita S et al. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study. J Dermatol 2020; 47: 629-635.
Babai S, Voisin AL, Bertin C, Gouverneur A, Le-Louet H. Occurrences and outcomes of immune checkpoint inhibitors-induced vitiligo in cancer patients: a retrospective cohort study. Drug Saf 2020; 43: 111-117.
Teulings HE, Limpens J, Jansen SN et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: A systematic review and meta-analysis. J J Clin Oncol 2015; 1: 773-781.
Hasan Ali O, Bomze D, Ring SS et al. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol 2020; 82: 854-861.
Flatz L, Berner F, Bomze D et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol 2019; 5: 1043-1047.
Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features. J Am Acad Dermatol 2020; 83: 1130-1143.
Arbour KC, Mezquita L, Long N et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 2018; 36: 2872-2878.
Scott SC, Pennell NA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol 2018; 13: 1771-1775.
Fucà G, Galli G, Poggi M et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open 2019; 4: e000457.
Apalla Z, Sibaud V. Immunotherapy-mediated dermatological adverse events: the urgent need for a common, clinically meaningful, management strategy. Support Care Cancer 2020; 28: 5597-5599.
Ständer S, Weisshaar E, Mettang T et al. Clinical classification of itch: A position paper of the international forum for the study of itch. Acta Derm Venereol 2007; 87: 291-294.
Common Terminology Criteria for Adverse Events (CTCAE). Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
Phillips GS, Wu J, Hellmann MD et al. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol 2019; 37: 2746-2758.
Belum VR, Benhuri B, Postow MA et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60: 12-25.
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 2018; 19: 345-361.
Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-2697.
Phillips GS, Freites-Martinez A, Wu J et al. Clinical characterization of immunotherapy-related pruritus among patients seen in 2 oncodermatology clinics. JAMA Dermatol 2019; 155: 249-251.
Champiat S, Lambotte O, Barreau E et al. Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. Ann Oncol 2016; 27: 559-574.
Puzanov I, Diab A, Abdallah K et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017; 5: 95.
Grávalos C, Sanmartín O, Gúrpide A et al. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2019; 21: 556-571.
Santini D, Vincenzi B, Guida FM et al. Aprepitant for management of severe pruritus related to biological cancer treatments: A pilot study. Lancet Oncol 2012; 13: 1020-1024.
Ito J, Fujimoto D, Nakamura A et al. Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer 2017; 109: 58-61.
Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Cur Opin Oncol 2016; 28: 254-263.
Curry JL, Tetzlaff MT, Nagarajan P et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol 2017; 44: 158-176.
Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015; 76-83.
Shi VJ, Rodic N, Gettinger S et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 2016; 152: 1128-1136.
Barrios DM, Phillips GS, Geisler AN et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol 2021; 32: 736-745.
Lacouture ME, Wolchok JD, Yosipovitch G, Kähler KC, Busam KJ, Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 2014; 71: 161-169.
Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372-8377.
Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer 2017; 41: 125-128.
Geisler AN, Phillips GS, Barrios DM et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 2020; 83: 1255-1268.
Inno A, Metro G, Bironzo P et al. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Tumori 2017; 103: 405-421.
de Golian E, Kwong BY, Swetter SM, Pugliese SB. Cutaneous complications of targeted melanoma therapy. Curr Treat Options Oncol 2016; 17: 57.
Bonigen J, Raynaud-Donzel C, Hureaux J et al. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol 2017; 31: 254-257.
Nikolaou V, Sibaud V, Fattore D et al. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. J Am Acad Dermatol 2021; 84: 1310-1320.
Voudouri D, Nikolaou V, Laschos K et al. Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer 2017; 41: 407-412.
Weber JS, Hodi FS, Wolchok JD et al. Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol 2017; 35: 785-792.
Dulos J, Carven GJ, Van Boxtel SJ et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 2012; 35: 169-178.
Rademaker M, Rubel DM, Agnew K et al. Psoriasis and cancer. An Australian/New Zealand narrative. Australas J Dermatol 2019; 60: 12-18.
Amatore F, Villani AP, Tauber M, Viguier M, Guillot B. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatology Venereol 2019; 33: 464-483.
Fattore D, Annunziata MC, Panariello L, Marasca C, Fabbrocini G. Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast. Eur J Cancer 2019; 110: 107-109.
Apalla Z, Psarakis E, Lallas A, Koukouthaki A, Fassas A, Smaragdi M. Psoriasis in patients with active lung cancer: is apremilast a safe option? Dermatol Pract Concept 2019; 9: 300-301.
Schafer PH, Parton A, Capone L et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal 2014; 26: 2016-2029.
Salopek TG. Recurrence of melanoma after starting apremilast for psoriasis. Case Rep Dermatol 2017; 9: 108-111.
Singh BP, Marshall JL, He AR. Workup and management of immune-mediated colitis in patients treated with immune checkpoint inhibitors. Oncologist 2020; 25: 197-202.
Hwang SJE, Park JJW, Wakade D, Chou S, Byth K, Fernandez-Penas P. Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-Associated protein 4 therapy use in patients with metastatic melanoma. Melanoma Res 2019; 29: 172-177.
Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol 2019; 80: 990-997.
Rovers JFJ, Bovenschen HJ. Dermatological side effects rarely interfere with the continuation of checkpoint inhibitor immunotherapy for cancer. Int J Dermatol 2020; 59: 1485-1490.
Schaberg KB, Novoa RA, Wakelee HA et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol 2016; 43: 339-346.
Wang LL, Patel G, Chiesa-Fuxench ZC et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol 2018; 154: 1057-1061.
Sibaud V, Eid C, Belum VR et al. Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings. J Eur Acad Dermatol Venereol 2017; 31: 464-469.
Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD, Lacouture ME. Eruptive keratoacanthomas associated with pembrolizumab therapy. JAMA Dermatol 2017; 153: 694-697.
Siegel J, Totonchy M, Damsky W et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol 2018; 79: 1081-1088.
Pereira MP, Steinke S, Zeidler C et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatology Venereol 2018; 32: 1059-1065.
Fixsen E, Patel J, Selim MA, Kheterpal M. Resolution of pembrolizumab-associated steroid-refractory lichenoid dermatitis with cyclosporine. Oncologist 2019; 24: 103-105.
Quach HT, Dewan AK, Davis EJ et al. Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma. JAMA Oncol 2019; 5: 906-908.
Hua C, Boussemart L, Mateus C et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016; 152: 45-51.
Larsabal M, Marti A, Jacquemin C et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol 2017; 76: 863-870.
Juzot C, Sibaud V, Amatore F et al. Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study. J Eur Acad Dermatology Venereol 2021; 35: 511-514. https://doi.org/10.1111/jdv.17253.
Verheyden MJ, Bilgic A, Murrell DF. A systematic review of drug-associated bullous pemphigoid. Acta Derm Venereol 2020; 100: adv00224.
Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol 2018; 57: 664-669.
Kosche C, Owen JL, Sadowsky LM, Choi JN. Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature. Dermatol Online J 2019; 25: 13030.
Apalla Z, Lallas A, Delli F et al. Management of immune checkpoint inhibitor-induced bullous pemphigoid. J Am Acad Dermatol 2021; 84: 540-543.
Nelson CA, Singer S, Chen T et al. Reply to: “Comment on Bullous pemphigoid after anti-PD-1 therapy: a retrospective case-control study evaluating impact on tumor response and survival outcomes”. J Am Acad Dermatol 2020; S0190-9622(20)30854-9.
Naidoo J, Schindler K, Querfeld C et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 2016; 4: 383-389.
Schwartzman G, Simpson MM, Jones R, Schiavone K, Coffman M, Meyerle J. Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer. Cutis 2020; 105: 9-12.
Molina GE, Reynolds KL, Chen ST. Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross-sectional study. Br J Dermatol 2020; 183: 1126-1128.
Sibaud V, Vigarios E, Siegfried A, Bost C, Meyer N, Pages-Laurent C. Nivolumab-related mucous membrane pemphigoid. Eur J Cancer 2019; 121: 172-176.
Li M, Huang L, Ren X et al. The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis. Medicine (Baltimore) 2020; 99: 22555.
Belum VR, Marulanda K, Ensslin C et al. Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol 2015; 26: 2496-2502.
Freites-Martinez A, Chan D, Sibaud V et al. Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. J JAMA Dermatol 2019; 155: 724-728.
Antoury L, Maloney NJ, Bach DQ, Goh C, Cheng K. Alopecia areata as an immune-related adverse event of immune checkpoint inhibitors: A review. Dermatol Ther 2020; 33: e14171.
Rivera N, Boada A, Bielsa MI et al. Hair repigmentation during immunotherapy treatment with an anti-programmed cell death 1 and anti-programmed cell death ligand 1 agent for lung cancer. JAMA Dermatol 2017; 153: 1162-1165.
Dasanu CA, Lippman SM, Plaxe SC. Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer. J Oncol Pharm Pract 2017; 23: 638-640.
Bertolini M, McElwee K, Gilhar A, Bulfone-Paus S, Paus R. Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol 2020; 29: 703-725.
Strazzulla LC, Wang EHC, Avila L et al. Alopecia areata: An appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol 2018; 78: 15-24.
Freites-Martinez A, Shapiro J, van den Hurk C et al. Hair disorders in cancer survivors. J Am Acad Dermatol 2019; 80: 1199-1213.
Di Altobrando A, Bruni F, Alessandrini A, Starace M, Misciali C, Piraccini BM. Severe de-novo palmoplantar and nail psoriasis complicating Nivolumab treatment for metastatic melanoma. Dermatol Ther 2020; 33: e13363.
van Damme C, Sibaud V, André J, Richert B, Berlingin E. Anti-PD-1-induced lichenoid changes of the nail unit: Histopathologic description. JAAD Case Rep 2021; 10: 110-112.
Elosua-González M, Pampín-Franco A, Mazzucchelli-Esteban R et al. A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy. Dermatol Online J 2017; 23: 13030.
Edwards C, Fearfield L. Nivolumab-induced lichenoid dermatitis occurring in a patient with metastatic melanoma successfully treated with alitretinoin. Clin Exp Dermatol 2018; 43: 609-610.
Xu Y, Wen N, Sonis ST, Villa A. Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women’s Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. Cancer 2021; 127: 1796-1804.
Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer 2017; 25: 1713-1739.
Shah N, Cohen L, Seminario-Vidal L. Management of oral reactions from immune checkpoint inhibitor therapy: A systematic review. J Am Acad Dermatol 2020; 83: 1493-1498.
Hofmann L, Forschner A, Loquai C et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 190-209.
Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol 2018; 19: 31-39.
Shazib MA, Bin WS et al. Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series. Oral Dis 2020; 26: 325-333.
Ortiz Brugués A, Sibaud V, Herbault-Barrés B et al. Sicca syndrome induced by immune checkpoint inhibitor therapy: optimal management still pending. Oncologist 2020; 25: 391-395.
Warner BM, Baer AN, Lipson EJ et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist 2019; 24: 1259-1269.
Mavragani CP, Moutsopoulos HM. Sicca syndrome following immune checkpoint inhibition. Oncologist 2019; 24: 1259-1269.
Le Burel S, Champiat S, Routier E et al. Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy. Ann Rheum Dis 2018; 77: 468-470.
Rapoport BL, van Eeden R, Sibaud V et al. Supportive care for patients undergoing immunotherapy. Support Care Cancer 2017; 25: 3017-3030.
Apalla Z, Kemanetzi C, Papageorgiou C et al. Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case. Dermatol Ther 2021; 34: e14618.
Mobini N, Dhillon R, Dickey J, Spoon J, Sadrolashrafi K. Exclusive cutaneous and subcutaneous sarcoidal granulomatous inflammation due to immune checkpoint inhibitors: report of two cases with unusual manifestations and review of the literature. Case Rep Dermatol Med 2019; 2019: 6702870.
Chen WS, Tetzlaff MT, Diwan H et al. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. J Cutan Pathol 2018; 45: 764-773.
Herrscher H, Tomasic G, Castro GA. Generalised morphea induced by pembrolizumab. Eur J Cancer 2019; 116: 178-181.
De Simone C, Mannino M, Sollena P, Deilhes F, Sibaud V, Peris K. Morphea-like changes in the setting of cancer immunotherapy. J Eur Acad Dermatol Venereol 2021; 35: 684-685. https://doi.org/10.1111/jdv.17388.
Salamaliki C, Solomou EE, Liossis SC. Immune checkpoint inhibitor-associated scleroderma-like syndrome: a report of a pembrolizumab-induced “eosinophilic fasciitis-like” case and a review of the literature. Rheumatol Ther 2020; 7: 1045-1052.
Tomelleri A, Campochiaro C, De Luca G, Cavalli G, Dagna L. Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. Eur J Intern Med 2018; 57: 11-12.
Do MH, Barrios DM, Phillips GS et al. Dermatologic infections in cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol 2021; 85: 1528-1536. S0190-9622(21)00586-7. https://doi.org/10.1016/j.jaad.2021.03.039.
Maloney NJ, Ravi V, Cheng K, Bach DQ, Worswick S. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review. Int J Dermatol 2020; 59: 183-188.
VigiAccess [Internet]. [cited 2021 Apr 16]. Available from: http://www.vigiaccess.org/.
Di Palma-Grisi JC, Vijayagopal K, Muslimani MA. Case reports of DRESS syndrome and symptoms consistent with DRESS syndrome following treatment with recently marketed monoclonal antibodies. Autoimmune Dis 2019; 2019: 7595706.
Mirza S, Hill E, Ludlow SP, Nanjappa S. Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome. Melanoma Res 2017; 27: 271-273.
Raschi E, Antonazzo IC, La Placa M, Ardizzoni A, Poluzzi E, De Ponti F. Serious cutaneous toxicities with immune checkpoint inhibitors in the U.S. food and drug administration adverse event reporting system. Oncologist 2019; 24: 1228-1231.
Page B, Borradori L, Beltraminelli H, Yawalkar N, Hunger RE. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab. J Eur Acad Dermatol Venereol 2018; 32: 256-257.
Matsubara T, Uchi H, Haratake N et al. Acute generalized exanthematous pustulosis caused by the combination of pembrolizumab plus chemotherapy in a patient with squamous-cell carcinoma. Clin Lung Cancer 2020; 21: 54-56.
González-Herrada C, Rodríguez-Martín S, Cachafeiro L et al. Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. J Invest Dermatol 2017; 137: 2092-2100.
Choi J, Anderson R, Blidner A et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Support Care Cancer 2020; 28: 6145-6157.